Toronto Dominion Bank
SAGE

Toronto Dominion Bank’s Sage Therapeutics SAGE Stock Holding History

Toronto Dominion Bank’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,082,120
Closed -$9.87M – 2076
2025
Q2 		$9.87M Buy
+1,082,120
New +$7.96M 0.02% 583
2025
Q1 		– Sell
-136,723
Closed -$742K – 1671
2024
Q4 		$742K Buy
+136,723
New +$836K ﹤0.01% 1120
2019
Q4 		– Sell
-25
Closed -$4K – 1512
2019
Q3 		$4K Buy
25
+23
+1,150% +$3.85K ﹤0.01% 1346
2019
Q2 		$0 Buy
+2
New +$341 ﹤0.01% 1702

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Toronto Dominion Bank's SAGE Position: Q3 2025 in Review

Toronto Dominion Bank sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,082,120 shares — an estimated $9.87M sold.

Toronto Dominion Bank first reported a position in SAGE in Q2 2019 and held it in 4 quarters. The position peaked at $9.87M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Toronto Dominion Bank reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Toronto Dominion Bank sold 1,082,120 Sage Therapeutics shares in Q3 2025, an estimated $9.87M.
  • Toronto Dominion Bank first reported a position in Sage Therapeutics in Q2 2019 and held it in 4 quarters.
  • Toronto Dominion Bank's Sage Therapeutics position peaked at $9.87M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Toronto Dominion Bank's 13F filing for Q3 2025, filed 14 Nov 2025.